Chapter 16

Organs-on-Chips: Mimicking Human Physiology for Drug Testing

Wisdom Leaf Press
Pages number, 78–82

https://journals.icapsr.com/index.php/wlp
DOI: 10.55938/wlp.v1i1.96

Digvijay Singh[1] and Mohammed Ismail Iqbal[2]

Abstract

Modern civilization encounters challenges with averting sickness and increasing life expectancy. Understanding illness causes and establishing effective therapy options with minimal adverse effects are the two primary approaches. Organs-on-chips (OOC) technology attempts to satisfy this demand by offering resource-efficient, miniature micro-physiological systems for biomedical research. Prior to clinical trials, drug researchers attempt to anticipate the adverse reactions of medications. OOC technology, which replicates human biological functions for enhanced safety and efficacy testing in preclinical studies, addresses the escalating expense of drug development due to inadequate forecasting in 2D cell culture and animal models. Traditional in vitro culture technologies and animal models are utilized to investigate viral infection pathology and develop treatments and vaccinations. However, there is an absence of simulations that adequately recreate human infection reactions. Researchers are exploring the possibility through tissue engineering as a bioelectronic alternative to animal cell cultures. OOC biosystems, microfluidic devices with customized micro-environments, have demonstrated applications in tissue engineering and drugs delivery. They have been employed in biomedicine to recreate organ operations and investigate interrelationships between various systems. Human organ-on-a-chip microfluidic culture technologies promise to satisfy this need. The paper highlights the potential benefits of OOC platforms for drug research, emphasizing their cost savings and possibilities for enhanced drug screening. It also addresses the barriers and opportunities that these systems present, as well as future projections for this technology.

Keywords

Organ-On-Chip (OOC), Microfluidics, Microengineered Biomimetic System, 3D cell Culture Systems, Drug Development

[1]Centre of Excellence for Energy and Eco-Sustainability Research (CEER), Uttaranchal University, Dehradun, Uttarakhand, India. digvijaysingh019@gmail.com
[2]College of Engineering and Technology, University of technology and sciences, NIZWA. mohammed.iqbal@utas.edu.com

Corresponding author
Email id: mohammed.iqbal@utas.edu.com

1. Introduction

The organ-on-chip (OOC) is an emerging technology which incorporates cell biology, engineering, and biomaterials to generate a physiological organ biomimetic system on a microfluidic chip. This system simulates the structure and function of human tissue, anticipating responses to stimuli involving medication reactions and environmental influences, making it valuable for precision medicine and biological defense tactics [1]. Cell culture innovations have revolutionized drug testing approaches, and microfluidics devices constitute a substantial breakthrough. OOC technologies enable live cells to replicate physiological processes of specific tissues or organs, including complicated biochemical interactions and physical pressures that include shear stress, mechanical stretching, or compression [2]. Stem cell biology and microfluidics technology have transformed in vitro screening platforms for the customized screening of medications, nutrients, chemicals, and nutraceuticals. Induced pluripotent stem cells, organoids, and OOC models have all made significant advances. These approaches promote efficiency in medication development and chemical safety testing [3]. OOCs are microfluidic devices which employ controlled, dynamic microenvironments in which cultivated cells imitate organ-level function. Blood samples, primary human tissue, and stem cell-derived cells may all be 'personalized' to represent individual physiology. This enables person-specific pharmacological efficacy and safety inspections, as well as individualized disease preventive and treatment plans, sometimes known as 'precision medicine' [4]. OOC is a microengineered biomimetic device with characteristics and functions similar to human tissue. It integrates engineering, cell biology, and biomaterial technologies on a tiny platform. OOC may boost preclinical testing success rates and predict drug effects in clinical trials. Biomedical engineers that specialize in device engineering are critical for moving innovations from university labs to specialized product development institutions and the expanding market [5]. Current in-vitro 2D cultures and animal experiments have constraints in their capacity to precisely replicate human physiopathology and estimate medication effectiveness and adverse effects. Micro-physiological systems, OOC, and multiorgan microdevices are being considered as potential novel techniques for high-throughput research and tailored medication discovery [6]. The inadequate predictive value of animal models in drug research for human effects is a major concern, as drug disposition can vary considerably between experimental human beings and animals. Classic in vitro methods lack the complexity required for replicating comprehensive physiological processes in the human body, prompting the creation of more predictive approaches in the preclinical phase [7]. Traditional animal testing and two-dimensional cell culture have restrictions that prevent their progress in research and therapeutic applications. OOC is a revolutionary method that accurately duplicates human tissues and organs while managing microenvironment and cellular patterns [8].

2. Mimicking Human Physiology for Drug Testing

The organ-on-chip (OOC) microengineered biomimetic system, which replicates human organ biology and physiology, surpasses conventional approaches for pharmacological effectiveness and safety evaluation. It eliminates interspecies disparities in disease pathways and gene expression patterns while integrating biomimetic microsystems into a single microdevice connected via a microfluidic circulatory pathway [9]. Innovative devices could offer insights into human organ function and disease pathology, adequately anticipate treatment safety and efficacy, and potentially substitute traditional preclinical cell culture and in vivo animal investigations. Over the last decade, the OOC market has experienced significant breakthroughs in biology and engineering, as well as physiological implications and applications

[10]. Semi-permeable membranes, continuous fluid perfusion, and integrated microdevices are some of the components of innovative OOC technology. These 3D cell culture systems replicate human organs, from respiration to heartbeat. This technique is predicted to strengthen cell biology research, customized medicine, drug development, and cancer diagnosis and treatment, thus enhancing precision medicine and medication development [11]. OOC technology, which simulates human organs on a chip, could be incorporated across the drug development process, from early discovery to preclinical screening, testing, and translation, bridging the gap between animal research and clinical trials. This innovative approach has the potential to transform the drug-development process [12]. Microfluidic OOC culture devices are gaining popularity in virology research owing to their ability to replicate human physiology and disease states, enabling investigations into viral infection, virus-host interactions, therapy-resistance evolution, and the development of new antiviral therapeutics. Recent advances have effectively replicated a variety of viral illness characteristics [13]. OOC culture technology, incorporates human physiology, microfluidics, tissue engineering, and stem cell biology, transforms drug screening and preclinical research. It eliminates the ethical and translational concerns associated with animal models, while offering a tool to investigate tissue development and homeostasis [14]. OOC biosystems establish regulated micro-environments comparable to those found in legitimate tissues for organ grown cells. These biocompatible polymer-based devices include micro-chambers and micro-channels for cell housing, nutrition, and growth factors. They have proven beneficial for tissue engineering and medication delivery, as well as modeling organ functions and studying the interactions of various systems [15]. Drug development is under increasing competition from the pharmaceutical industry and healthcare services, with effectiveness and safety evaluations critical for cost and time savings. Advances in micro-fabrication and tissue engineering have resulted in OCC, an in vitro model that could simulate human organ functions and provide insight into disease pathophysiology, providing an efficient alternative to animal models for preclinical drug screening [16]. Microfluidic organ-chips investigate organ physiology and disease by simulating the tissue micro-environment and utilizing human cells. This eliminates the constraints of animal models, and 3D printing allows researchers to reproduce natural tissues for implants and regenerative scaffolding [17]. Liver-on-a-chip (Liver Chip) platforms are 3D micro-physiological systems that better comprehend human liver physiology and pathology, allowing them to anticipate human outcomes. These devices simulate in vivo settings by replicating the sinusoidal shape of the liver, retaining high cell viability, and imitating natural liver activities [18]. Physiologically based pharmacokinetic (PBPK) modeling is an intriguing approach for drug development since it accurately simulates in vivo drug absorption, distribution, metabolism, and excretion processes than standard models, possibly eliminating animal testing [19]. OOC platforms are microfluidic devices used in drug screening and disease metabolic research that integrate additive manufacturing with microfluidics to reproduce physiological and biological features of organs and tissues employing human-derived cells [20].

3. Recommendations

We propose the following recommendations for successful implementation of Organ-On-Chip approaches for enhancing the general life-style of the individuals in the modern society.

- Future possibilities include 3D printing for individualization, rapid prototyping, and multi-material processing of next-generation Organ Chips. Current investigations depend upon high-content microscopy images, and integrating them with screening assays involving metabolomics, sensors, and single-cell sequencing might give solutions.

- Organ-on-a-chip (OOC) technology might be leveraged to create human illness designs, particularly for pediatric and rare conditions, with the design and implementation of human-body-on-a-chip becoming critical in the future.
- OOC innovations, unlike typical cell culture methods, provide substantial candidates for modeling and investigating hitherto unexplored organs, with benefits over in vivo model animals and regulated stimulation for stem cells.
- The establishment of a fully developed and validated multiorgan-on-chip model provides numerous advantages, including faster and more cost-effective drug development, boosted disease treatment accessibility, improved testing of chemicals and food components, and the substitution of ethically sensitive animal tests with in vitro methods.
- Collaborations between academics, regulators, contract research organizations, and industry are critical for validating improved in vitro simulations. Despite its inventive nature, academia lacks the facilities, resources, and experience required to get beyond early prototypes and attain technological maturity.
- The primary goal of OOC is to incorporate multiple organs onto a single chip, culminating in a sophisticated multi-organ chip model. Considering the high manufacturing and experimental expenses, components must be low-cost, easy to dispose of, and recyclable. For common usage, the media volume and connection size should be lowered.
- Patient-derived tissues, cells, and organoids can substantially minimize animal testing that produce inaccurate predictions for the human population and may be employed early in pharmaceutical research, particularly in drug discovery.
- The incorporation of cutting-edge technical techniques including autonomous handling, 3D printing, in situ multisensors, and biological ideas like patient-specific induced pluripotent stem cells and organoids would substantially enhance its biomedical capabilities.

Conclusion

Drug research is evolving rapidly attributable to advances in technology involving in vitro replications of human tissues, illnesses, and multi-organ models. These approaches boost throughput and resource efficiency while outperforming standard 2D culture systems and animal testing. Modern organ-on-chip technologies offer opportunity for better comprehension of disease pathways, with significant milestones already achieved. Organ-on-a-chip technologies have proven beneficial for transforming in vitro studies into clinical research as they maintain the organ's microenvironment and can possibly be utilized for examining the pharmaceutical characteristics of specific medications. These microfluidic devices are encouraging significant collaborations between academics and industry, which might assist in accelerating the creation of effective medications for crucial organs linked with fatal illnesses. They can also be combined to actuator systems, allowing for medication delivery on demand continuously. This study examines current advances in organ-on-a-chip technology, encompassing the lung, digestive system, heart, liver, and vasculature, along with its applications in pharmaceutical screening and customized healthcare. It suggests incorporating human-on-a-chip nanotechnology to better understand human physiology and pathology.

ORCID iDs

Digvijay Singh https://orcid.org/0000-0003-3640-3891
Mohammed Ismail Iqbal https://orcid.org/0000-0001-6636-7014

References

1. Wu, Q., Liu, J., Wang, X., Feng, L., Wu, J., Zhu, X. ... Gong, X. (2020). Organ-on-a-chip: Recent breakthroughs and future prospects. *Biomedical engineering online*, *19*, 1–19.
2. Lacombe, J., Soldevila, M., & Zenhausern, F. (2022). From organ-on-chip to body-on-chip: The next generation of microfluidics platforms for in vitro drug efficacy and toxicity testing. *Progress in Molecular Biology and Translational Science*, *187*(1), 41–91.
3. van Berlo, D., Nguyen, V. V., Gkouzioti, V., Leineweber, K., Verhaar, M. C., & van Balkom, B. W. (2021). Stem cells, organoids, and organ-on-a-chip models for personalized in vitro drug testing. *Current Opinion in Toxicology*, *28*, 7–14.
4. Van Den Berg, A., Mummery, C. L., Passier, R., & Van der Meer, A. D. (2019). Personalised organs-on-chips: functional testing for precision medicine. *Lab on a Chip*, *19*(2), 198–205.
5. Ahmed, T. (2022). Organ-on-a-chip microengineering for bio-mimicking disease models and revolutionizing drug discovery. *Biosensors and Bioelectronics: X*, *11*, 100194.
6. Monteduro, A. G., Rizzato, S., Caragnano, G., Trapani, A., Giannelli, G., & Maruccio, G. (2023). Organs-on-chips technologies–A guide from disease models to opportunities for drug development. *Biosensors and Bioelectronics*, *231*, 115271.
7. van Berlo, D., van de Steeg, E., Amirabadi, H. E., & Masereeuw, R. (2021). The potential of multi-organ-on-chip models for assessment of drug disposition as alternative to animal testing. *Current Opinion in Toxicology*, *27*, 8–17.
8. Zhou, C., Li, Z., Lu, K., Liu, Y., Xuan, L., Mao, H., & Wang, X. (2024). Advances in Human Organs-on-Chips and Applications for Drug Screening and Personalized Medicine. *Fundamental Research*.
9. Zhu, J. (2020). Application of organ-on-chip in drug discovery. *Journal of Biosciences and Medicines*, *8*(3), 119–134.
10. Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021). Organs-on-chips: into the next decade. *Nature Reviews Drug Discovery*, *20*(5), 345–361.
11. Zarrintaj, P., Saeb, M. R., Stadler, F. J., Yazdi, M. K., Nezhad, M. N., Mohebbi, S. ... Mozafari, M. (2022). Human Organs-on-Chips: A Review of the State-of-the-Art, Current Prospects, and Future Challenges. *Advanced Biology*, *6*(1), 2000526.
12. Ma, C., Peng, Y., Li, H., & Chen, W. (2021). Organ-on-a-chip: a new paradigm for drug development. *Trends in pharmacological sciences*, *42*(2), 119–133.
13. Tang, H., Abouleila, Y., Si, L., Ortega-Prieto, A. M., Mummery, C. L., Ingber, D. E., & Mashaghi, A. (2020). Human organs-on-chips for virology. *Trends in microbiology*, *28*(11), 934–946.
14. Jalili-Firoozinezhad, S., Miranda, C. C., & Cabral, J. M. (2021). Modeling the human body on microfluidic chips. *Trends in biotechnology*, *39*(8), 838–852.
15. Seidi, S., Eftekhari, A., Khusro, A., Heris, R. S., Sahibzada, M. U. K., & Gajdács, M. (2022). Simulation and modeling of physiological processes of vital organs in organ-on-a-chip biosystem. *Journal of King Saud University-Science*, *34*(1), 101710.
16. Wang, Y., Gao, Y., Pan, Y., Zhou, D., Liu, Y., Yin, Y. ... Song, Y. (2023). Emerging trends in organ-on-a-chip systems for drug screening. *Acta Pharmaceutica Sinica B*, *13*(6), 2483–2509.
17. Jain, A., Mathur, T., Pandian, N. K., & Selahi, A. (2020). Organ-on-a-chip and 3D printing as preclinical models for medical research and practice. *In Precision medicine for investigators, practitioners and providers* (pp. 83–95). Academic Press.
18. Moradi, E., Jalili-Firoozinezhad, S., & Solati-Hashjin, M. (2020). Microfluidic organ-on-a-chip models of human liver tissue. *Acta biomaterialia*, *116*, 67–83.
19. Yang, Y., Chen, Y., Wang, L., Xu, S., Fang, G., Guo, X. ... Gu, Z. (2022). PBPK modeling on organs-on-chips: An overview of recent advancements. *Frontiers in Bioengineering and Biotechnology*, *10*, 900481.
20. Tabatabaei Rezaei, N., Kumar, H., Liu, H., Lee, S. S., Park, S. S., & Kim, K. (2023). Recent advances in organ-on-chips integrated with bioprinting technologies for drug screening. *Advanced healthcare materials*, *12*(20), 2203172.